CDXS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CD

Mkt Cap

$135.2M

Volume

895.50K

Next Earnings

November 5th

Loading chart

CD

CDXSCodexis, Inc.

CDXS

Pay with—

Available Balance0.00

CD

Mkt Cap

$148.9M

Volume

895.50K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Codexis Announces Pricing of Public Offering of Common StockCodexis, Inc. announced the pricing of an underwritten public offering of 16.67 million shares at $1.50 per share, generating approximately $23.1 million in net proceeds. The company plans to use the funds for working capital, research, development, and general corporate purposes. The offering is expected to close on July 27, 2026, with Piper Sandler and Cantor serving as joint bookrunning managers.GlobeNewswire Inc. · Jul 24, 2026

Codexis to Participate in Cantor Global Healthcare ConferenceCodexis, a provider of enzymatic solutions for therapeutics manufacturing, will participate in the Cantor Global Healthcare Conference in New York on September 4, 2025, presenting a live webcast of their fireside chat.GlobeNewswire Inc. · Aug 28, 2025

Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNACodexis presented data at TIDES USA showcasing its ECO Synthesis platform's ability to support siRNA manufacturing, including reduced purification costs, improved process performance, and potential to control stereochemistry. Three CDMOs also validated the transferability of Codexis' ligation processes.GlobeNewswire Inc. · May 22, 2025

Codexis Announces Byron Dorgan to Retire from Board of DirectorsCodexis announced that Byron Dorgan will retire from the company's Board of Directors, and the company is developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.GlobeNewswire Inc. · Apr 9, 2025

Specialty Enzymes Market to Expand at 7.5% CAGR, Reaching USD 10.7 Billion by 2032 | SNS InsiderThe Specialty Enzymes market is growing rapidly due to increasing applications in food, beverages, and pharmaceuticals. Advancements in science and increasing consumer knowledge of the benefits of health are key driving factors. The market is expected to reach USD 10.7 Billion by 2032, growing at a CAGR of 7.5%.GlobeNewswire Inc. · Feb 20, 2025

Global Artificial Sweeteners Market to Observe Growth at a CAGR of ~4% by 2030 | DelveInsightThe global artificial sweeteners market is expected to grow at a CAGR of around 4% from 2024 to 2030, driven by the increasing demand for low-calorie foods due to the rising rates of diabetes, hypertension, and obesity, as well as ongoing research and development efforts leading to new product launches.GlobeNewswire Inc. · Dec 4, 2024

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy AssetsREDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty.GlobeNewswire Inc. · Jul 1, 2024

Codexis to Participate in Jefferies Global Healthcare ConferenceREDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6, 2024, in New York, New York.GlobeNewswire Inc. · May 22, 2024

Codexis to Participate in TD Cowen 2nd Annual Sustainability WeekREDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, “Sustainable API Manufacturing” at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024. During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics.GlobeNewswire Inc. · May 20, 2024

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual MeetingREDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic manufacturing milestone are being presented today in a Spotlight Presentation at the TIDES USA annual meeting taking place in Boston, MA, and virtually May 14 – 17, 2024.GlobeNewswire Inc. · May 14, 2024

to start trading

CD

CDXSCodexis, Inc.

CDXS

Pay with—

Available Balance0.00

Your PositionYou don't own any CDXS yet.

Related Tickers

Earnings